Patient Satisfaction With Abbreviated Postpartum Magnesium Sulfate for Severe Preeclampsia
NCT05789381 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL
Last updated 2024-11-08
Summary
Preeclampsia is a common and potentially devastating disease that affects only pregnant or postpartum patients. It is a leading cause of maternal mortality not only worldwide, but in the United States as well. As the medical field has advanced in many regards, including improved treatment for prevention of severe preeclampsia or even eclamptic seizures, the strain on pregnant and postpartum people has remained relatively unchanged. The most successful and widely used management of severe preeclampsia is magnesium sulfate, an intravenous infusion used to help prevent eclamptic seizures which can be additionally life threatening. While magnesium can be efficacious, it comes with some hindrances. Notably, magnesium itself can make patients feel ill-weak, confused, lethargic, "foggy", and even somnolent in cases of toxicity. Other adverse effects include pulmonary edema, and cardiac arrhythmias or even coma. These effects are common and concerning enough that it is regular practice to examine patients at the bedside with a full neurological exam every 2 hours while they are on magnesium, which is typically a course of at least 24 hours straight. Additionally, patients typically have a foley catheter in place to monitor urine output as magnesium can cause kidney injury, and they are bedbound because of the lethargy and concern for falls. In the postpartum period this has significant negative impacts on patients bonding with their newborn, initiating breast or chest feeding, walking, voiding, and aiding in faster postpartum recovery. While the implications of a life threatening medical diagnosis are devastating for many patients, the trauma that can be caused by being away from a patient's newborn or not feeling in control of the patients own body postpartum are issues that are finally starting to be recognized. While magnesium is necessary, there may be ways to treat patients while maintaining independence, mental health and sense of selves especially in the sensitive postpartum period. The investigators hypothesis is that, in a carefully selected group of patients with severe preeclampsia, 12 hours of magnesium sulfate leads to improved patient satisfaction, increased breastfeeding postpartum, as well as other markers of enhanced postpartum recovery, and lack of worsening symptoms or persistently elevated blood pressure in comparison to 24 hours of magnesium.
Conditions
- Patient Satisfaction
Interventions
- PROCEDURE
-
Magnesium sulfate
This drug is commonly used on labor and delivery and in the postpartum period and is easily ordered through the electronic medical record and provided. This drug requires no specific storage for research study purposes as the drug is already being administered per standard of care and national and international guidelines. The only change is in the duration of therapy. This is NOT considered an off label use of the drug and does not require any form of exemption determination. Magnesium for severe preeclampsia is often given for anywhere from 12 to 24 hours postpartum depending on the clinical scenario, provider preference, and patient symptoms/adverse reactions to the medication.
Sponsors & Collaborators
-
University of Chicago
lead OTHER
Principal Investigators
-
Joana Lopes Perdigao, MD · University of Chicago
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2024-03-01
- Primary Completion
- 2024-03-01
- Completion
- 2024-03-01
More Related Trials
-
Magnesium Sulfate in Pregnancy and Postpartum
NCT02317146 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Efficacy and Safety of 1 g Vs 2 g Per Hour Intravenous Maintenance Dose of MgSO4 in Women With Severe Pre-eclampsia
NCT03164304 ·Status: COMPLETED ·Phase: PHASE4
-
Magnesium Sulfate in Obese Preeclamptics
NCT02835339 ·Status: COMPLETED ·Phase: PHASE4
-
Comparison of Loading Dose Magnesium Sulphate With Prichard Regimen in the Management of Severe Preeclampsia and Eclampsia.
NCT06126068 ·Status: COMPLETED ·Phase: NA
-
Low Dose Magnesium Sulphate Versus Standard Pritchard Regimen In Management Of Severe Preeclampsia/Eclampsia
NCT04501289 ·Status: COMPLETED ·Phase: NA
-
The Effect of Magnesium on Maternal Mood, Cognitive Function, and Birth Experience
NCT02454322 ·Status: COMPLETED
-
A Randomized Clinical Trial of Oral Magnesium Supplementation in Pregnancy
NCT02032186 ·Status: COMPLETED ·Phase: PHASE3
-
New Magnesium Sulphate Protocol for Pre-eclampsia
NCT01846156 ·Status: COMPLETED ·Phase: PHASE3
-
Serum Magnesium Concentration in Magnesium Sulfate Therapy for Severe Preeclampsia
NCT05283473 ·Status: COMPLETED
-
Treatment Approaches to Preeclampsia
NCT01030627 ·Status: COMPLETED ·Phase: PHASE4
-
Different Regimens of Magnesium Sulphate in Patients With Severe Preeclampsia
NCT06791668 ·Status: RECRUITING
-
Preeclampsia Postpartum Antihypertensive Treatment
NCT04298034 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Trial Comparing Treatment With the Springfusor Infusion Pump to the IV Magnesium Sulfate Regimen
NCT02091401 ·Status: COMPLETED ·Phase: PHASE4
-
Management of Postpartum Preeclampsia
NCT05775744 ·Status: COMPLETED ·Phase: NA
-
Role of L-citrulline in Prevention of Pregnancy Associated Hypertension
NCT04979793 ·Status: SUSPENDED ·Phase: PHASE1
-
Effect of Magnesium Sulphate on the Intracranial Pressure of Preeclamptic Patients
NCT03210350 ·Status: COMPLETED
-
In Utero Magnesium Sulfate Exposure: Effects on Extremely-Low-Birth-Weight Infants
NCT01203501 ·Status: COMPLETED
-
Restrictive Fluid Therapy in Severe Preeclampsia
NCT02214186 ·Status: COMPLETED ·Phase: NA
-
Labetalol Versus Magnesium Sulfate (MgSO4) for the Prevention of Eclampsia Trial
NCT00293735 ·Status: WITHDRAWN ·Phase: PHASE2/PHASE3
-
Detection of Epileptiform Activity in Severe Preeclampsia
NCT03494517 ·Status: UNKNOWN
-
12-hour Versus 24-hour Postpartum Magnesium Sulphate for Preeclamptic Patients
NCT04576364 ·Status: COMPLETED ·Phase: NA
-
Use of Cheetah® Cardiac Monitoring System to Guide Discontinuation of Magnesium Sulfate in Women With Severe Preeclampsia
NCT04474704 ·Status: COMPLETED ·Phase: NA
-
The Effect of Loading Dose of Magnesium Sulfate on Uterine, Umbilical, and Fetal Middle Cerebral Arteries Doppler, Biophysical Profile, CTG, Maternal Vital Signs in Women With Severe Preeclampsia
NCT03891498 ·Status: UNKNOWN ·Phase: NA
-
Chronic Remote Ischemic Preconditioning as a Complement to Conventional Prenatal Care for Preeclampsia
NCT05564988 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Pregnancy Salt Substitution Trial for Hypertensive Disorders of Pregnancy Prevention (PREG-Salt)
NCT07294807 ·Status: NOT_YET_RECRUITING ·Phase: NA